They may sound like they are similar because they phosphoramidate conjugates, but the active drugs in fact are very different. If you wanted to compare TH-302 to something - Ifosfamide would be the closest comparison. Ifosfamide is what they based the active part of TH-302 on and ifos is a widely accepted chemotherapy drug. I think it’s very naive or perhaps ill informed to say Telcyta and TH-302's drugs are anything alike except in the fact they share a base in a phosphoramidate conjugates. It's like saying water and hydrochloric acid are similar because they both share a hydrogen base.
Telcyta was stopped because it was actually causing women to die faster... I assumed that it was toxicity problems - but I guess if the control arm drug was actually working and theirs wasn't... I wasn’t involved in TELK and didn’t care enough to really dig into the data. I'm not defending TELK or their drug but I am saying that it’s a fallacious argument when you say that TH-302 is the same active drug as Telcytra was because they are both phosphoramidate conjugates. I am sure I don’t have to tell you that changing a few bonds or atoms here and there can create a very different compound. And the active compounds are very different.
Based on the Telcyta results the women might have done better putting antifreeze into their system. Telcyta was a flop but Telik management was imo criminally negligent for not stopping these ph3 trials.
"The woman treated with Telcyta died more than five months faster than similar woman in the control arm of the study.
The median survival time for women in the Telcyta arm of Assist-1 was 8.5 months. The women in the control arm of the study treated with the approved drugs doxorubicin or topetecan reported a median survival time of 13.6 months."
Market Data 
Markets 
AI
